Brief: Pharmather Announces Exclusive License Agreement With The University Of Arizona For The Commercialization Of Ketamine
15/10/2020 14:04
Oct 15 (Reuters) - Newscope Capital Corporation PHRM.CD :
* PHARMATHER ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH THE
UNIVERSITY OF ARIZONA FOR THE COMMERCIALIZATION OF KETAMINE IN
THE TREATMENT OF PARKINSON’S DISEASE
Source text for Eikon: ID:nGNX3BQq64
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application